Cited by 243RNA Interference and Gene DeliveryCRISPR and Genetic EngineeringNanoparticle-Based Drug Delivery

Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

Open access
Zhang, Di, Wang, Guoxun, Yu, Xueliang, Wei, Tuo, Farbiak, Lukas, Johnson, Lindsay T., Taylor, Alan Mark, Xu, Jiazhu +3 more·2022·Nature Nanotechnology

Abstract

Genome editing holds great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR/Cas to solid tumours for efficient cancer therapy remains challenging. Here we targeted tumour tissue mechanics via a multiplexed dendrimer lipid nanoparticle (LNP) approach involving co-delivery of focal adhesion kinase (FAK) siRNA, Cas9 mRNA and sgRNA (siFAK + CRISPR-LNPs) to enable tumour delivery and enhance gene-editing efficacy. We show that gene editing was enhanced >10-fold in tumour spheroids due to increased cellular uptake and tumour penetration of nanoparticles mediated by FAK-knockdown. siFAK + CRISPR-PD-L1-LNPs reduced extracellular matrix stiffness and efficiently disrupted PD-L1 expression by CRISPR/Cas gene editing, which significantly inhibited tumour growth and metastasis in four mouse models of cancer. Overall, we provide evidence that modulating the stiffness of tumour tissue can enhance gene editing in tumours, which offers a new strategy for synergistic LNPs and other nanoparticle systems to treat cancer using gene editing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41565-022-01122-3

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lipid nanoparticle (LNP) have been found to co-deliver Cas9 mRNA, focal adhesion kinase (FAK) siRNA, and sgRNA to improve both tumor delivery and gene editing efficacy.

    “Lipid nanoparticle (LNP) have been found to co-delivery of Cas9 mRNA, focal adhesion kinase (FAK) siRNA, and sgRNA to improve both tumor delivery and gene editing efficacy.55”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [55]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhang, D., Wang, G., Yu, X., Wei, T., Farbiak, L., Johnson, L. T., Taylor, A. M., Xu, J., Hong, Y., Zhu, H., & Siegwart, D. J.
Affiliations
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • The University of Texas at Arlington (US)
Corresponding author
Siegwart, Daniel J.
Venue
Nature Nanotechnology
Published
2022-05-12
Volume
17
Issue
7
Pages
777-787
ISSN
  • 1748-3387 (ISSN-L)
  • 1748-3395
OpenAlex
W4280596283
Cited by
243
References
52
Citations by year
2026: 35 · 2025: 77 · 2024: 56 · 2023: 62 · 2022: 13
FWCI
16.98
Type
journal article
Language
en
Open access
Locations
  • Nature Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Cancer Prevention and Research Institute of Texas (RP160157, RP190251)
  • Pharmaceutical Research and Manufacturers of America Foundation (Predoctoral Fellowship in Drug Delivery)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA251928, 5P30CA142543, R01 CA269787-01)
  • U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB025192-01A1)
  • American Cancer Society (RSG-17-012-01)
  • Welch Foundation (I-1855)
  • Cystic Fibrosis Foundation (SIEGWA18XX0)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
CRISPR gene editing, extracellular matrix stiffness, focal adhesion kinase, siRNA knockdown, tumor spheroids, cancer immunotherapy, metastasis suppression
MeSH terms
Gene Editing, Animals, Liposomes, Neoplasms, Gene Transfer Techniques, Mice, Nanoparticles, B7-H1 Antigen, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review